Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07419841 · ClinicalTrials.gov registry record · Phase 1

A Phase 1 Study of the Safety and Tolerability of CTX-10726

A Phase 1 study, sponsored by Compass Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
70
Enrollment target

NCT07419841: Recruiting Phase 1 study, sponsored by Compass Therapeutics.

NCT07419841 is a Phase 1 study that is actively recruiting participants, run by Compass Therapeutics. The registered enrollment target is 70 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07419841, a Phase 1 study, is actively recruiting participants, sponsored by Compass Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
70 participants
Enrollment target

Study Summary

This is a Phase 1, open-label, first-in-human study of CTX-10726 monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 Cohorts: Cohort 1 Dose Escalation and Cohort 2 Dose Expansion.

Primary Outcome

Incidence of dose limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs), and/or changes in clinical laboratory abnormalities.

Interventions

  • DRUG CTX-10726

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2026-05-28
Est. Completion 2028-11-01
Phase Phase 1
Compass Therapeutics

5 total trials

What NCT07419841 shows while recruiting

NCT07419841 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% higher).

The record links to 0 conditions, and to 1 intervention - of which CTX-10726 is the first listed.

NCT07419841 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07419841 about?

NCT07419841 is a clinical study titled "A Phase 1 Study of the Safety and Tolerability of CTX-10726". This is a Phase 1, open-label, first-in-human study of CTX-10726 monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 Cohorts: Cohort 1 Dose Escalation and Cohort 2 Dose Expansion.

What is the current status of trial NCT07419841?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2026-05-28. Estimated completion is 2028-11-01.

What interventions are being tested in trial NCT07419841?

The interventions under investigation include: CTX-10726 (DRUG).

Who is sponsoring clinical trial NCT07419841?

This trial is sponsored by Compass Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07419841's enrollment target sits among peer trials

70 749th of 2000 higher than 1,227 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00969111 · 70 participants · NA

    Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy

  • NCT01712620 · 70 participants · Phase 2

    Spironolactone for Pulmonary Arterial Hypertension

  • NCT02143830 · 70 participants · Phase 2

    HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

  • NCT02601339 · 70 participants

    NIRS Monitoring in Premature Infants

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07419841, the US trial registry maintained by the National Library of Medicine. NCT07419841 (small enrollment · none site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.